Well, that was fast. Seventy seven days after Aiolos Bio launched to the public, GSK has disclosed a deal to buy the biotech and its phase 2 asthma treatment for $1 billion upfront and up to $400 million in regulatory milestones.
GSK has weighed up the competition and bet up to $1.4 billion on AIO-001. In a statement, Tony Wood, chief scientific officer at GSK, called AIO-001 a potentially best-in-class medicine that could expand the company’s biologics portfolio to the 40% of severe asthma patients with low T2 inflammation.
Post-hoc analyses of phase 2/3 trials of Tezspire linked the antibody to reductions in exacerbations in T2 low asthmas, a subgroup that other drugs, including GSK’s Nucala and phase 3 prospect depemokimab, aren’t designed to treat. Tezspire’s broad efficacy led the FDA to make it the first asthma drug approved for severe asthma without phenotypic limitations, such as eosinophilic, or biomarker restrictions.
The belief that AIO-001 can improve on Tezspire rests, in part, on its dosing schedule. Tezspire is given subcutaneously once a month. GSK believes the “enhanced potency and half-life extension technology” of AIO-001 could support dosing every six months. The Big Pharma’s work on the HIV drugs Cabenuva and Apretude has shown how longer-lasting medicines can win market share.
The deal represents another successful exit for Aiolos CEO Khurem Farooq, who co-founded the biotech with Tony Adamis, M.D., after leading Gyroscope Therapeutics to an $800 million takeover by Novartis.